FIELD: medicine.
SUBSTANCE: in patient's urine content of 6-sulfatoximelatonin is determined. If determined content of 6-sulfatoximelatonin after operation before complex treatment equals 292.7 nmol/ml survival to 2.3±0.5 months is predicted, if 22.4 nmol/ml is determined, survival for more than 12 months is predicted. If after chemical therapy determined content of 6-sulfatoximelatonin equals 268.2 nmll/ml, predicted survival time equals to 2.1±0.6 months, if content is 32.8 nmol/ml - more than 12 months. If after a month after treatment determined content of 6-sulfatoximelatonin equals 479.3 nmol/ml predicted is survival for 1.2±0.5 months, in case of 37.4 nmol/ml - survival for more than 12 months.
EFFECT: increased accuracy of predicting survival of patients with low-differentiated glial brain tumours.
7 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ADJUVANT CHEMOTHERAPY OF MALIGNANT CEREBRAL GLIOMAS | 2010 |
|
RU2466739C2 |
| METHOD OF PREDICTING DEVELOPMENT OF CEREBRAL METASTASES IN CASE OF LUNG CANCER IN WOMEN | 2009 |
|
RU2439579C2 |
| METHOD OF PREDICTING DEVELOPMENT OF PATHOLOGICAL PROCESS DIRECTION IN PATIENTS WITH BRAIN TUMOURS | 2009 |
|
RU2433410C2 |
| METHOD FOR CHEMORADIATION THERAPY OF BRAIN MALIGNANT GLIAL TUMOR | 2005 |
|
RU2296567C1 |
| METHOD FOR SPECIFYING DIRECTIONALITY OF PATHOLOGICAL PROCESS IN LUNG CANCER | 2009 |
|
RU2440037C2 |
| METHOD OF LOCAL CHEMOTHERAPY OF MALIGNANT GLIAL BRAIN TUMOURS | 2009 |
|
RU2392987C1 |
| COMBINED METHOD FOR TREATING CENTRAL NERVE SYSTEM MALIGNANT TUMOR CASES | 2005 |
|
RU2307655C2 |
| METHOD FOR ASSAY OF TREATMENT EFFICACY OF PATIENTS WITH INTRACEREBRAL MALIGNANT TUMORS | 2003 |
|
RU2255745C2 |
| METHOD FOR TREATING MALIGNANT SPINAL CORD TUMOR CASES WITH CHEMOTHERAPY | 2004 |
|
RU2280446C2 |
| METHOD OF PREDICTING OF PROCESS ACTIVATION IN PATIENTS WITH HODGKIN'S LYMPHOMA | 2009 |
|
RU2405454C1 |
